Accepted for Publication: October 1, 2013.
Published Online: November 4, 2013. doi:10.1001/jamasurg.2013.5022.
Study concept and design: Sarwer, Wadden, Rosen.
Acquisition of data: Spitzer, Mitchell, Lancaster, Courcoulas, Gourash.
Analysis and interpretation of data: Sarwer, Mitchell, Rosen, Christian.
Drafting of the manuscript: Sarwer, Spitzer, Rosen, Christian.
Critical revision of the manuscript for important intellectual content: Sarwer, Wadden, Mitchell, Lancaster, Courcoulas, Gourash, Rosen, Christian.
Statistical analysis: Christian.
Obtained funding: Sarwer, Wadden, Mitchell, Rosen.
Administrative, technical, or material support: Sarwer, Spitzer, Courcoulas, Gourash.
Study supervision: Sarwer, Mitchell, Rosen.
Conflict of Interest Disclosures: Dr Sarwer has served as a paid consultant for Allergan, BariMD, BAROnova, EnteroMedics, and Ethicon Endo-Surgery, which are manufacturers of products for nonsurgical weight loss treatment and bariatric surgery. At the time of the conduct of the study, he also was on the board of directors of the Surgical Review Corporation, which created the International Center of Excellence for Bariatric Surgery program to evaluate bariatric surgeons and hospitals around the world. Dr Wadden serves on advisory boards for Novo Nordisk and Orexigen Pharmaceuticals. Dr Courcoulas has received research grants from Allergan, Pfizer, Covidien, EndoGastric Solutions, and Nutrisystem and is on the scientific advisory board of Ethicon J&J Healthcare System. No other disclosures were reported.
Funding/Support: This ancillary study to the LABS-2 was funded by National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK072452.
Role of the Sponsors: The National Institute of Diabetes and Digestive and Kidney Diseases provided funding support for the study. The Program Officers provided input on the design and execution of the study.
Additional Information: This article is to be presented on November 14, 2013, at Obesity Week in Atlanta, Georgia.